


COVID-19 patient experiences in prehospital pathways: a processual approach using life-events calendar method and state sequence analysis shows detrimental delays

Romain Lutaud ^{1,2}, Sebastien Cortaredona,³ Lea Delorme,⁴ Patrick Peretti-watel,⁵ Juliette Mirouse,¹ Manon Borg,¹ Lucie Cattaneo,⁴ Didier Thery,¹ Gaetan Gentile,¹ Christian Pradier,⁶ Touitou Irit,⁶ Philippe Brouqui,⁷ Sophie Tardieu,⁸ Michel Carles,⁹ Stéphanie Gentile⁸

To cite: Lutaud R, Cortaredona S, Delorme L, *et al*. COVID-19 patient experiences in prehospital pathways: a processual approach using life-events calendar method and state sequence analysis shows detrimental delays. *Fam Med Com Health* 2024;**12**:e002447. doi:10.1136/fmch-2023-002447

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/fmch-2023-002447>).



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Romain Lutaud;
romain.lutaud@univ-amu.fr

ABSTRACT

Objectives To our best knowledge, no study in France has comprehensively investigated the prehospital history of patients admitted for severe cases of COVID-19. 'Patients' voice is an excellent means to capture data on primary care pathways.

We aimed to identify clusters of COVID-19 hospitalised patients with similar prehospital symptom sequences, and to test whether these clusters were associated with a higher risk of poor clinical outcomes.

Design Cross-sectional online survey using life-event calendars.

Setting All patients hospitalised for COVID-19 between September 2020 and May 2021 in the Infectious Disease Departments in Nice and in Marseilles in France.

Participants 312 patients responded to the survey.

Main outcome measures From the day of symptom onset to the day of hospitalisation, we defined a symptom sequence as the time-ordered vector of the successive symptom grades (grade 1, grade 2, grade 3). State sequence analysis with optimal matching was used to identify clusters of patients with similar symptom sequences. Multivariate logistic regressions were performed to test whether these clusters were associated with admission to intensive care unit (ICU) and COVID-19 sequelae after hospitalisation.

Results Three clusters of symptom sequences were identified among 312 complete prehospital pathways. A specific group of patients (29%) experienced extended symptoms of severe COVID-19, persisting for an average duration of 7.5 days before hospitalisation. This group had a significantly higher probability of being admitted to ICU (adjusted OR 2.01). They were less likely to know a loved one who was a healthcare worker, and more likely to have a lower level of education. Similarly, this group of patients, who were more likely to have previously visited the emergency room without exhibiting severe symptoms at that time, may have been inclined to postpone reassessment when their health worsened.

Their relatives played a decisive role in their hospitalisation.

KEY POINTS

- ⇒ **Question** We wanted to better understand whether direct recourse to the hospital system by COVID-19 patients with serious symptoms was because of the natural history of the disease (ie, sudden clinical deterioration) or because of delays in the system's primary care pathway.
- ⇒ **Findings** A specific group of patients in France with severe symptoms of COVID-19 during the first wave of the pandemic experienced a delay before hospitalisation which was detrimental to their health. Family and friends played a crucial role in hospitalisation, while lower education levels and lack of familiarity with healthcare professionals resulted in delays. Similarly, this group of patients, who were more likely to have previously visited the emergency room without exhibiting severe symptoms at that time, may have been inclined to postpone reassessment when their health worsened.
- ⇒ **Meaning** The processual approach revealed the interconnectedness of life, medical and clinical events in care pathways, emphasising the significance of biology, personal history and social context.

Conclusion and relevance This study highlights the negative impact of delayed hospitalisation on the health outcomes of French patients with severe COVID-19 symptoms during the first wave and underscores the influence of socioeconomic factors, such as lower education levels and limited connections to the medical field, on patients' experiences.

INTRODUCTION

Over the last decade, analysing patient experience has been one of the pillars for assessing the quality of care pathways.¹ A care pathway can be understood as the outcome of clinical and non-clinical events related

to the natural history of the disease and to the ways in which the patient interprets symptoms and mobilises his/her use of the health system.² Care pathways have rarely been approached as a process, that is to say a trajectory unfolding over time and structured by sequences of events.³⁻⁵ In order to comprehensively assess the effect of time on care pathways, it is important to take into account the order of event sequences and the amount of time that passes for each sequence.^{6,7}

The fight against COVID-19 not only involves therapeutic advances but also improved clinical management of symptomatic patients. The latter depends on how patients orientate themselves in the care system and whether they choose to access care or not. A national French study showed that during the first wave of COVID-19, nearly 20% of COVID-19 patients were admitted to hospital after arriving in an emergency department (ED); 11% of these were immediately admitted to an intensive care unit (ICU).⁸ In another study, a cohort of 2111 adults hospitalised at the Infectious Diseases Department of the University Hospital of Nice (CHU hereafter) and its sister department in Marseille (IHU hereafter), 53% were referred to these departments after arrival at the respective ED and three-quarters of all those who died had been admitted to hospital after arriving in an ED, including those immediately admitted to an ICU.⁹

To improve primary (ie, prehospital) care management for COVID-19, with a view to improving disease prognosis, it is important to study patients' primary care pathways, particularly those of patients admitted immediately to an ICU after consulting in an ED.¹⁰

This study is the first to use patients' experiences to describe and interpret all the events structuring primary (ie, prehospital) care pathways in persons hospitalised (ie, consulting in an ED and then either discharged or transferred to a hospital department) for COVID-19 in France during the pandemic's first wave. Studying patients' experiences during the first wave was a relevant methodological choice, as changes in health authority guidelines empowered people to make health management decisions, by requesting them to identify signs of severity and indications for diagnostic tests at home, and more generally, to decide on whether to go to a hospital ED or not.

We implemented an innovative mixed-method approach comprising a life-events calendar combined with a sequence analysis with a view to better understanding primary care management of patients with COVID-19, by giving priority to clinical events, to the chronological sequence of these events, and to the way actors (ie, patients and doctors) interpreted and reacted to them. More specifically, the study's objectives were to (a) describe outpatient pathways by characterising the natural course of the disease and understanding how certain variables act at key time points in a care trajectory (ie, how they trigger hospitalisation); (b) identify patterns/clusters of patients with similar outpatient pathways using a state sequence analysis (SSA); (c) test whether

these patterns/clusters were associated with a higher risk of poor clinical outcomes in terms of both admission to an ICU during hospitalisation, and COVID-19 sequelae after release from hospital.

METHODS

Design and study population

We performed a cross-sectional online survey between 17 May and 2 July 2022. It targeted patients hospitalised for COVID-19 between September 2020 and May 2021 in the IHU and CHU. All patients were eligible irrespective of their mode of entry to the hospitals (ie, via ED, immediate admission, etc). Patients who died before the start of the survey were excluded. Because we anticipated a relatively low response rate, we did not apply any sampling to our target population. A phone interview was also proposed to patients whose physical condition might have hampered their ability to respond to the online questionnaire.

Life-events calendar method

This article presents the quantitative phase of a mixed-methods research study comprising an exploratory qualitative phase and a quantitative phase. The qualitative phase aimed to identify all the possible types of primary (ie, prehospital) care pathways and different outpatient patient management strategies for persons hospitalised with diagnosed COVID-19 infection in France. It also aimed to test the suitability of using the life-events calendar tool to prepare the questionnaire used during the quantitative phase. A life-events calendar is a retrospective data collection tool which highlights the chronological order and proximity of clinical events and major transitions in care trajectories, making it possible to simultaneously analyse several aspects of the patient's global care pathway (ie, clinical history, diagnostic pathway, care pathway, therapeutic pathway) (online supplemental material 1).^{11,12}

All materials and database of this study are openly available online (recherche.data.gouv.fr).¹³

Sample size and response rate

A phone number was retrieved for 2608 (80.0%) of the 3259 eligible patients. The former were asked to provide their email address if they wished to participate. Of the 944 who provided a valid email address to receive the link to the online questionnaire, 312 answered the survey. As sex, age and site (Marseille/Nice) all had a significant impact on participation, we decided to weight the sample. The final weights were created using an iterative process (ranking ratio estimation) involving data (sex, age and site) collected on the eligible population.

Assessment of COVID-19 symptom timeline

Patients were asked about their daily COVID-19 symptom timeline from illness onset (ie, day of symptom onset) to the beginning of their hospitalisation for COVID-19. This timeline allowed us to register the type and number of

symptoms reported each day as well as the sequence in which each new symptom appeared. Patients could report up to 17 different symptoms for each day. We then classified the symptoms into three grades representing the level of clinical severity, with symptoms being cumulative.

1. Grade 1 symptoms: fever (moderate or intense), cough, muscular pain, fatigue (moderate or intense), headache (moderate or intense), nausea (moderate or intense), diarrhoea, anosmia/ageusia
2. Grade 2 symptoms: grade 1 symptoms+breathing difficulty (moderate or intense), oxygen desaturation.
3. Grade 3 symptoms: grade 1 and 2 symptoms+confusion, loss of consciousness.

These three grades made it possible to distinguish between symptoms that required: (a) ambulatory (ie, non-hospital based) management (grade 1); (b) hospitalisation (ie, ED consultation and possible admission to hospital (excluding ICU) (grade 2) according to the French Higher Authority for Health criteria); (c) admission (whether immediate or not) to an ICU (grade 3, life-threatening emergencies).

For each patient, we defined a symptom sequence as the time-ordered vector of their successive symptom grades ('grade 1', 'grade 2', 'grade 3'). Therefore, the length of each individual sequence was not the same for all patients as it depended on the number of days which elapsed from the day of symptom onset to the day of hospitalisation for COVID-19. If symptoms from different grades were declared for the same day (eg, symptoms from grades 2 and 3), the symptom of the highest grade was retained.

Assessment of covariates

In order to evaluate factors likely to be associated with symptom onset sequences, we collected sociodemographic (age, sex, occupation and education level) and clinical (number of comorbidities/medical history, obesity and smoking status) data. Patients were asked whether they had consulted a general practitioner (GP), day hospital (ie, outpatient clinic at the IHU/CHU) or an emergency care service before their hospitalisation for COVID-19. They were also asked about the treatment(s) they had been prescribed.

The survey also collected data on patients' difficulties to see a doctor and/or receive treatment before their hospitalisation, whether they knew a loved one (ie, family member or friend) who was a healthcare worker, and the person who decided the patient had to be hospitalised (GP, emergency care service, family member, patient him/herself).

Ascertainment of clinical outcomes

As regards the clinical outcomes, patients were asked about the length of their hospital stay, ICU admission, follow-up care/rehabilitation/home oxygen treatment after release from hospital, and whether they still had COVID-19 sequelae at the time of the survey.

Statistical analysis

To characterise the clinical history typology (ie, clusters of patients with similar symptom sequences), we performed an SSA. An SSA is a non-parametric method used to analyse sequential data. Key aspects include sequencing (the order of distinct state occurrence), duration (the length of spell in a specific health state (ie, grades 1, 2 and 3 here)) and timing (the moment of transition from one state to another).^{14 15} The method aims to compare all individual sequences with each other to establish a dissimilarity matrix between sequences. A clustering method can then be applied on this matrix to identify clusters of individuals with typical sequences. We chose optimal matching (OM) as the method to assess dissimilarity between symptom sequences.^{14 16 17} OM measures dissimilarity as the weighted sum of the number of virtual editing operations (substitution, insertion and deletion) required to transform one individual's sequence into another's. For this analysis, a constant substitution cost of 2 and an insertion/deletion cost of 1.5 were chosen. These values allowed us to take into account the different dimensions (sequencing, timing, duration and spell duration). We also tested three different combinations of substitution and insertion/deletion costs (1/2, 2/1 and 2/3) to check the robustness of our results. For the clustering step, we used a hierarchical cluster analysis (HCA) applied to the dissimilarity matrix. To compare clustering solutions based on different quality measures, we used the Weighted Cluster¹⁸ library in R. The prevalence of each cluster and the relevance of the solutions were also considered. Once clusters were defined, chronograms (cross-sectional distribution of states) and sequence index plots (longitudinal order of states) were plotted to visualise the typical sequences of symptoms for each cluster.

Cluster characteristics were compared using the χ^2 test. We also performed two multivariate logistic regressions to test whether the clusters of symptom sequences were associated with ICU admission and COVID-19 sequelae at the time of the survey. Both models were adjusted for the main risk factors associated with a poor clinical outcome¹⁹ (ie, age, gender, number of comorbidities/clinical history, obesity and smoking status). Models were also adjusted for socioeconomic factors (ie, education level).

All analyses involved two-sided p values, with statistical significance defined as a p value ≤ 0.05 . Data preparation, sequence creation, descriptive statistics and regression analyses were conducted using SAS V.9.4 (SAS Institute, Cary, NC, USA). SSA and HCA were performed using the TraMineR²⁰ and WeightedCluster¹⁸ libraries in R V.4.2.2.

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

RESULTS

The study population included 312 patients (table 1) hospitalised for COVID-19. The average time from the day of symptom onset to the beginning of hospitalisation was 6.7 ± 3.6 days (min=1, max=16). As regards the clinical outcomes, the average hospital stay was 10.8 ± 12.8 days, 50.6% were admitted to an ICU, and 52.6% had follow-up or rehabilitation care after being released from hospital. Half (49.1%) declared sequelae at the time of the survey, physical sequelae being most frequent (40.6%) followed by neurological sequelae (30.8%).

In terms of symptom onset, moderate fever was the most frequent symptom reported (34.2%) (figure 1), followed by a cough (27.8%), moderate fatigue (22.1%), muscular pain (20.3%) and intense fatigue (19.8%). Putting this in terms of grades, 88.1%, 28.6% and 1.0% reported at least one grade 1, grade 2 or grade 3 symptom, respectively. At the beginning of hospitalisation, intense fatigue (31.4%), moderate fever (25.4%), moderate breathing difficulties (21.7%) and oxygen desaturation (20.8%) were the most frequent symptoms. Putting this in terms of grades, 52.5%, 49.0% and 7.8% reported at least one grade 1, grade 2 or grade 3 symptom, respectively.

The SSA combined with the HCA (online supplemental material 2) identified three clusters (figure 2A,B, table 2), resulting in the typology of different symptom sequences from symptom onset to hospitalisation. To check the robustness of our clustering solution, we performed three sensitivity analyses in which we tested different combinations of substitution and insertion/deletion costs in the SSA analyses. The results were very stable (Cohen's Kappa coefficient >0.84 between the four clustering solutions).

The first cluster (cluster 1, 'grade 1 symptom(s)') (n=107, 34.3%) comprised patients with relatively long primary (ie, prehospital) care sequences (9.4 days on average). Compared with the two other clusters, most patients in cluster 1 reported grade 1 symptoms from day 1 to day 9. Grade 2 symptoms were more frequently reported after day 9 (figure 2). On average, these patients reported grade 1 symptoms for 7.4 days, grade 2 symptoms for 1.4 days and grade 3 symptoms for 0.6 days prior to hospitalisation.

The second cluster (cluster 2, 'short prehospital sequence') (n=144, 36.5%) comprised patients with relatively short primary care sequences compared with the two other clusters (4.3 days). On average, these patients reported grade 1 symptoms for 1.5 days, grade 2 symptoms for 2.3 days and grade 3 symptoms for 0.5 days prior to hospitalisation.

The last cluster (cluster 3, 'grade 2 symptom(s)') (n=91, 29.2%) comprised patients who reported grade 2 symptoms more frequently. The length of their primary care sequence was comparable to that for cluster 1 (ie, 9.9 days). However, in cluster 3, all patients reported at least one grade 2 symptom during their primary care sequence (vs 60.4% in cluster 1, $p<0.001$). On average, patients in cluster 3 reported grade 1 symptoms for

Table 1 Study population characteristics (n=312)

	n*	%†
Sex		
Female	128	41.1
Male	184	58.9
Age		
Mean (SD)	65.2 (13.8)	
18–49	47	15.0
50–64	97	31.1
65–79	106	34.1
>79	62	19.7
Site		
Marseille	248	79.7
Nice	64	20.3
Period		
2020	112	35.8
2021	200	64.2
Education		
<General certificate of secondary education	49	15.6
General certificate of secondary education	59	18.9
High school diploma	52	16.7
≥Diploma of higher education	152	48.7
Number of comorbidities/medical history		
None	97	31.1
One	85	27.3
Two	44	14.2
Three	42	13.4
More than three	44	14.0
Daily smoker	10	3.2
Obesity (body mass index ≥ 30 kg/m ²)	80	25.6
Live alone	77	24.6
Works/has worked as a healthcare worker	63	20.1
Knows someone in his/her close circle who is a healthcare worker	164	52.6
Time from symptom onset to hospitalisation (days) – mean(SD)	6.7 (3.6)	
Clinical outcomes		
Length of hospital stay (days) (nmiss=1)		
Mean (SD)	10.8 (12.8)	
Transfer to intensive care unit	158	50.6

Continued

Table 1 Continued

	n*	%†
Follow-up/rehabilitation care after hospitalisation	164	52.6
Home oxygen treatment after hospitalisation	176	56.6
Still has sequelae of COVID-19 at the time of the survey	153	49.1
Physical sequelae	126	40.6
Neurological sequelae	96	30.8
Psychological sequelae	57	18.2
Sleep disorders sequelae	51	16.5

*Weighted frequency otherwise stated; the sum may not add to 312 due to rounding.
 †Weighted column percentages otherwise stated; the sum may not add to 100% due to rounding.

2.0 days, grade 2 symptoms for 7.5 days and grade 3 symptoms for 0.4 days prior to hospitalisation.

In bivariate analyses (table 2), patients assigned to cluster 1 showed a higher likelihood of knowing a loved one who was a healthcare worker (61.5% vs 57.9% in clusters 2 and 3, p=0.022). This cluster also demonstrated a reduced likelihood of having undergone two or more

negative tests before the COVID-19 diagnosis compared with clusters 2 and 3 (3.3% vs 10.2%, p=0.032) and an increased likelihood of reporting treatment with antibiotics (69.6% vs 52.6%, p=0.004). The transfer to the ICU was also significantly lower in cluster 1 (43.0% vs 57.0%, p=0.050). In cluster 2, compared with clusters 1 and 3, the proportion of obese patients was significantly higher (32.7% vs 21.5%, p=0.028), and fewer patients declared that their COVID-19 diagnosis was confirmed after symptom onset (63.7% vs 77.5%, p=0.009). This cluster also exhibited a higher likelihood of having undergone two or more negative tests before the COVID-19 diagnosis (13.3% vs 4.8%, p=0.007). In a quarter of cases, it was a GP who decided the patient needed hospitalisation (23.7% vs 12.5%, p=0.011). Regarding the last cluster, compared with clusters 1 and 2, cluster 3 had a significantly lower proportion of patients aged >79 (12.4% vs 22.8%, p=0.036), a lower proportion of patients with a high education level (39.8% vs 52.4%, p=0.043), and a lower likelihood of knowing a loved one who was a healthcare worker (33.3% vs 60.6%, p<0.001). Furthermore, cluster 3 had a higher proportion of patients whose COVID-19 diagnosis was confirmed after symptom onset (84.7% vs 67.4%, p=0.002), a higher proportion of patients reporting difficulties in obtaining treatment (33.2% vs 19.7%, p=0.011), and a higher proportion of patients who had consulted an emergency service




Figure 1 Declared symptom(s) from symptom onset to hospitalisation (n=312). *First symptom(s) declared by the patient. **Last symptom(s) declared by the patient prior to hospitalization.




Figure 2 (A) Sequence index plots (each line represents a participant's symptom sequence). (B) Chronograms/state distribution plots (the plots show the distribution of states (grade 1, 2 and 3) for each time unit point (17 days). *Weighted frequency.

Table 2 Sociodemographic and clinical profiles of the three clusters of symptom sequences (n=312)

	Grade 1 symptom(s)		Short prehospital sequence		Grade 2 symptom(s)	
	n*	%†	n*	%†	n*	%†
n	107		114		91	
Sex						
Female	36	33.9	51	45.2	40	44.4
Male	71	66.1	62	54.8	51	55.6
Age						
Mean (SD)	66.4 (13.9)		65.3 (16.0)		63.7 (10.9)	
18–49	15	14.0	21	18.4	11	12.0
50–64	30	27.8	29	25.6	38	41.8**
65–79	40	37.2	36	31.5	31	33.9
>79	22	21.0	28	24.5	11	12.4*
Site						
Marseille	87	81.4	93	82.2	68	74.4
Nice	20	18.6	20	17.8	23	25.6
Period						
2020	33	31.1	40	35.5	38	41.8
2021	74	68.9	73	64.5	53	58.2
Education						
<General certificate of secondary education	13	12.4	23	20.0	13	13.8
General certificate of secondary education	21	19.7	15	13.6	22	24.7
High school diploma	16	14.6	17	14.7	20	21.7
≥Diploma of higher education	57	53.2	59	51.7	36	39.8*
Number of comorbidities/medical history						
None	29	27.1	40	35.6	27	30.0
One	29	27.1	28	24.4	28	31.1
Two	15	14.4	14	12.2	15	16.5
Three	19	17.7	14	12.4	9	9.7
More than three	15	13.7	17	15.3	12	12.7
Daily smoker	3	2.9	6	5.3	1	1.0
Obesity (body mass index ≥30 kg/m ²)	21	20.1	37	32.7*	21	23.0
Live alone	23	21.8	30	26.2	24	25.8
Works/has worked as a healthcare worker	26	24.0	22	18.9	15	16.9
Knows someone in his/her close circle who is a healthcare worker	66	61.5*	68	59.7	30	33.3***
COVID-19 diagnosis confirmed after symptom onset	76	71.4	72	63.7**	77	84.7**
Number of negative tests prior to confirmed COVID-19 diagnosis						
None	89	83.5	87	76.9	77	84.7
One	14	13.2	11	9.8	8	8.9
Two or more	4	3.3*	15	13.3**	6	6.4

Continued

**Table 2** Continued

	Grade 1 symptom(s)		Short prehospital sequence		Grade 2 symptom(s)	
	n*	%†	n*	%†	n*	%†
Declares having difficulties to see a doctor	31	28.7	24	21.0	28	30.6
Declares having difficulties to get treatment	23	21.5	20	18.0	30	33.2*
Has consulted a general practitioner‡	68	63.6	56	49.2*	53	58.3
Has consulted at 'day hospital'‡	56	52.2	53	46.6	34	37.4
Has consulted an emergency service‡	22	20.3	17	15.0	25	27.9*
Was aware of the seriousness of their health status prior to hospitalisation	41	38.0	48	42.7	36	39.7
Trigger of hospitalisation						
Family member	30	27.8	27	23.7	34	37.4*
General practitioner	13	11.9	27	23.7*	12	13.2
Emergency service	38	35.8	42	36.9	30	33.2
Patient	17	15.5	14	12.6	11	12.1
Prehospital treatments						
Antibiotics§	74	69.6**	62	54.3	46	50.5
No treatment¶	25	23.7*	41	36.2	34	37.5
Clinical outcomes						
Length of hospital stay (days) (nmiss=1)						
Mean (SD)	12.4 (17.3)		9.7 (10.7)		10.4 (8.8)	
Transfer to intensive care unit	46	43.0*	59	52.0	52	57.6
Follow-up/rehabilitation care after hospitalisation	56	52.4	53	46.7	55	60.2
Home oxygen treatment after hospitalisation	58	54.2	71	62.8	47	51.6
Still has sequelae of COVID-19 at the time of the survey	47	44.0	53	47.0	53	57.7*
Physical sequelae	37	34.4	47	41.4	43	46.7
Neurological sequelae	36	33.5	34	30.1	26	28.4
Psychological sequelae	22	21.0	15	12.8	20	21.7
Sleep disorders sequelae	15	14.2	22	19.4	14	15.6

*p<0.05, **p<0.01, ***p<0.001, respectively (weighted χ^2 test). The value in the cluster is compared to the remaining sample.

*Weighted frequency otherwise stated; the sum may not add to cluster size due to rounding.

†Weighted column percentages otherwise stated; the sum may not add to 100% due to rounding.

‡Between symptom onset and hospitalisation.

§Infectious diseases department of Marseille protocol included (hydroxychloroquine+azithromycin).

¶Paracetamol excluded.

Table 3 Association of intensive care unit admission and of COVID-19 sequelae at time of survey with symptom sequences clusters; adjusted multivariate logistic regressions (n=312)

	Admission to intensive care unit		COVID-19 sequelae at the time of survey	
	aOR 95% CI*	P value	aOR 95% CI*	P value
Female (ref. male)	0.41 (0.24 to 0.68)	<0.001	1.54 (0.93 to 2.56)	0.097
Age (years)	1.01 (0.99 to 1.03)	0.429	0.98 (0.96 to 1.00)	0.020
Education level (ref. <general certificate of secondary education)				
General certificate of secondary education	0.80 (0.34 to 1.88)	0.612	1.96 (0.84 to 4.59)	0.121
High school diploma	0.90 (0.38 to 2.15)	0.809	2.69 (1.12 to 6.45)	0.027
≥Diploma of higher education	0.56 (0.26 to 1.19)	0.131	1.18 (0.56 to 2.50)	0.661
Lived alone (ref. no)	1.08 (0.60 to 1.92)	0.805	1.07 (0.60 to 1.90)	0.829
Number of comorbidities/medical history (ref. none)				
One	0.87 (0.45 to 1.66)	0.669	2.54 (1.31 to 4.94)	0.006
Two	1.16 (0.54 to 2.49)	0.704	1.57 (0.73 to 3.37)	0.246
Three	1.33 (0.60 to 2.95)	0.485	2.01 (0.89 to 4.54)	0.094
More than three	0.79 (0.34 to 1.82)	0.576	2.06 (0.88 to 4.79)	0.095
Daily smoker (ref. no)	1.23 (0.31 to 4.91)	0.774	2.67 (0.58 to 12.26)	0.207
Obesity (ref. no)	1.92 (1.09 to 3.38)	0.023	1.48 (0.84 to 2.59)	0.175
Prehospital symptom sequence (ref. cluster 1: grade 1 symptom(s) sequence)				
Cluster 2: short prehospital sequence	1.51 (0.85 to 2.65)	0.157	1.10 (0.62 to 1.95)	0.744
Cluster 3: grade 2 symptom(s) sequence	2.01 (1.10 to 3.67)	0.024	1.54 (0.85 to 2.80)	0.159

*Adjusted OR with 95% CI.

(27.9% vs 17.6%, $p=0.039$). In over one-third of cases, a family member determined the need for hospitalisation (37.4% vs 25.7%, $p=0.038$). Additionally, the proportion of patients declaring persistent sequelae of COVID-19 at the time of the survey was significantly higher (57.7% vs 45.5%, $p=0.050$).

After adjustment for the main risk factors (table 3), patients assigned to cluster 3 had, all things being equal, a significantly higher risk of admission to an ICU (adjusted OR 2.01 (95% CI 1.10 to 3.60)) compared with those in cluster 1. The proportion of patients who declared sequelae at the time of the survey was not significantly higher after adjustment for the main risk factors (1.54 (0.85 to 2.80), $p=0.159$).

DISCUSSION

Our study shows that a significant proportion of hospitalised patients (cluster 3) had symptoms of severe COVID-19 (grade 2) for a long period of time (7.5 days on average) before being hospitalised. Patients in this cluster were more likely to have previously visited an ED for COVID-19-like symptoms, and more likely reported more difficulties with primary care (ie, prehospital) treatment. Compared with the other two clusters, they were less likely to know a loved one who was a healthcare

worker, and less likely to have a higher level of education (ie, diploma of higher education or higher).

These results suggest that this population was less integrated in the health system and had greater difficulty accessing primary care in general. Health inequalities, which have been the subject of a large number of publications, both on COVID and on the state of health in general.^{21–24}

We have identified four key reasons that may explain the delayed hospitalisation in cluster 3 despite the severity of COVID-19 symptoms:

1. Lack of healthcare professionals in the personal network: individuals without close connections to healthcare professionals may experience delays in seeking hospitalisation. The absence of immediate access to medical advice can contribute to a delay in recognising the severity of symptoms.
2. Absence of higher education credentials: those without a higher education background might face challenges in understanding the gravity of their symptoms or may be less likely to seek prompt medical attention due to a potential lack of health literacy.
3. Postponing reevaluation after recent emergency room visit: patients who have recently visited the emergency room and did not exhibit severe symptoms at that




Figure 3 Timeline of prehospital care pathways and main clinical outcomes.

time may be inclined to defer reevaluation when their health deteriorates. This delay could be attributed to a perceived lower risk based on the recent emergency room visit.

4. Perception of lower risk due to supposed health status: both patients and healthcare professionals may hold a misperception regarding the risk associated with individuals identified as belonging to a lower-risk population, such as those of intermediate age with fewer comorbidities. This collective misperception may lead to an underestimation of symptom severity, contributing to delays in hospitalisation despite the presence of alarming signs.

All these reasons may have prompted patients to postpone their decision to seek additional hospital care despite experiencing symptoms, waiting until a relative, friend or general practitioner expressed concern. The role of loved ones in triggering hospitalisation was a decisive resource for patients in cluster 3. The erratic primary care pathway described for patients in cluster 3 was detrimental, as they were two times as likely to be admitted to an ICU and to suffer from COVID-19 sequelae after release from hospital. These findings contrast with the pathway of comorbid patients at risk of severe COVID-19 infection who were closely monitored by their GP and who did not hesitate to be hospitalised very early after symptom onset. The results are summarised in [figure 3](#).

Strengths and weaknesses

This study has several potential limitations. First concern arises from selection bias, as our study exclusively includes survivors of COVID-19. It is recognised that non-survivors could constitute a more extreme subgroup, hinting at a potential fourth cluster marked by intensified symptoms before hospitalisation. This could affect the representativeness of our study population for all

hospitalised COVID-19 patients. To address this, an alternative approach could involve interviewing patients on hospital admission, extracting clinical outcomes from medical databases and conducting a follow-up interview 1 year later to assess COVID-19 sequelae. Second, as the survey was conducted using self-administered questionnaires, it was not possible to make an objective evaluation of each symptom or clinical event. Third, patients may have been subject to memory bias as the survey—which investigated their prehospital symptoms—took place between 13 and 20 months after hospitalisation. However, previous studies show that in the case of traumatic events, such as hospitalisation, patients often retain good memory of the events that led to their hospitalisation.^{25–27}

Despite these limitations, this study clearly identified a significant delay in management for patients with severe symptoms. The life-events calendar method allowed us to explore the clinical history of the patients with great precision, something we would not have otherwise been able to obtain. Specifically, the quantitative processing of care pathways⁷—made possible by OM—allowed us to (a) highlight important differences in care pathways, (b) test hypotheses to explain these pathways, (c) evaluate the impact of these care pathways on the clinical outbreak (admission to an ICU, sequelae after release from hospital) and (d) highlight the person who decided that the patient had to be hospitalised.

Suitability of the methodology used

In the literature to date, patient experience has been the domain of qualitative methods and patient reporting experience measures.^{28–33} Despite this, until now patients' experience has not been studied in depth in a contextualised way^{34 35} that is to say, has not been studied in the various objective elements of the care pathway. By using a processual approach using the life-events calendar

method and an SSA, we were able to combine patients' subjective experience with objective contextual data (medical records describing their hospitalisation history and their socio-clinical profiles). This combination helped us acquire a better understanding of their primary care pathways before hospitalisation.

Implications for research and clinical practices

The multidimensional perspective emphasises that effective care goes beyond medical interventions. It underscores the importance of addressing practical challenges and barriers that patients encounter in their daily lives.² This may involve collaboration with social services, community organisations, to ensure that patients have access to the necessary resources.

CONCLUSIONS

This study highlights the importance of temporality in primary care pathways and demonstrates that patients in France with severe symptoms of COVID-19 during the first wave of the pandemic experienced a delay before hospitalisation which was detrimental to their health. The processual approach revealed the interconnectedness of biology, personal history and social context.³⁶

Author affiliations

¹Department of General Practice, Aix-Marseille University, Marseille, France

²ADES, Marseille, France

³Institut de Recherche pour le Développement (IRD), Marseille, France

⁴Assistance Publique- Hôpitaux de Marseille (AP-HM), Marseille, France

⁵INSERM, Marseille, France

⁶Department of Public Health, Archet University Hospital, Nice, France

⁷MEPHI, Marseille, France

⁸CEReSS - Health Service Research and Quality of life Center, Marseille, France

⁹Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Nice, France

Contributors RL, SC, LD, PP-W, JM, MB, LC, DT, GG, CP, TI, PB, ST, MC and SG collectively conceived and designed the study. RL, SC and LD conducted analyses. RL, SC and SG drafted the manuscript. RL, SC, LD, PP-W, JM, MB, LC, DT, GG, CP, TI, PB, ST, MC and SG critically revised the manuscript. SG is responsible for the overall content

Funding This project was funded by Agence Nationale de la Recherche 'Résilience Covid-19' (ANR-21-COVR-0043).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by French North West IV Ethics Committee (authorisation N° EudraCT/ID-RCB: 2021-A01138-33, 2 July 2021). The authors had no personal relationship with the participants. All the patients contacted received an information letter and a non-opposition form in accordance with this ethics committee's guidelines. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. All materials and database of this study are openly available on recherche.data.gouv.fr [dataset]. Cortaredona S, Gentile S, Lutaud R, *et al.* Expérience patient & parcours préhospitalier des patients COVID-19. 2023. <https://doi.org/10.57745/7J9VEQ>.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Romain Lutaud <http://orcid.org/0000-0003-3443-5937>

REFERENCES

- Larson E, Sharma J, Bohren MA, *et al.* When the patient is the expert: measuring patient experience and satisfaction with care. *Bull World Health Organ* 2019;97:563–9.
- Meyers T. How is comorbidity lived. *Lancet* 2015;386:1128–9.
- Roux J, Grimaud O, Leray E. Use of state sequence analysis for care pathway analysis: the example of multiple sclerosis. *Stat Methods Med Res* 2019;28:1651–63.
- Vignier N, Desgrees Du Lou A, Pannetier J, *et al.* Social and structural factors and engagement in HIV care of sub-saharan african migrants diagnosed with HIV in the paris region. *AIDS Care* 2019;31:897–907.
- Desgrées-du-Loû A, Pannetier J, Ravalihasy A, *et al.* Sub-saharan african migrants living with HIV acquired after migration, france, anrs parcours study, 2012 to 2013. *Euro Surveill* 2015;20.
- Pailhé A, Robette N, Solaz A. Work and family over the life-course. A typology of french long-lasting couples using optimal matching. *LLCS* 2013;4:196–217.
- Abbott A, Tsay A. Sequence analysis and optimal matching methods in sociology. *Sociological Methods & Research* 2000;29:3–33.
- Courtejoie N, Dubost C. Parcours hospitalier des patients atteints de la COVID-19 lors de la première vague de L'épidémie. In: *DREES*. 2020. Available: <https://drees.solidarites-sante.gouv.fr/sites/default/files/2020-10/DD67.pdf>
- Arlotto S, Garès A, Giraud-Gatineau A, *et al.* Life-years lost by COVID-19 patients in public hospitals of marseille (APHM-south-eastern france): a limited death toll: a retrospective analysis. *BMJ Open* 2021;11:e049475.
- Le Borgne P, Oberlin M, Bassand A, *et al.* Pre-hospital management of critically ill patients with SARS-Cov-2 infection: a retrospective multicenter study. *J Clin Med* 2020;9:3744.
- Biographies D'Enquêtes*. In: *Biographies d'enquêtes - Bilan de 14 collectes biographiques - Groupe de réflexion sur l'approche biographique*. Paris, 2009.
- Lutaud R, Verger P, Peretti-Watel P, *et al.* When the patient is making the (wrong?) diagnosis: a biographical approach to patients consulting for presumed lyme disease. *Fam Pract* 2022;cmac116.
- Cortaredona S, Gentile S, Lutaud R, *et al.* Data from: expérience patient & parcours préhospitalier des patients COVID-19. 2023. Available: <https://doi.org/10.57745/7J9VEQ>
- Studer M, Ritschard G. What matters in differences between life trajectories: a comparative review of sequence dissimilarity measures. *J R Stat Soc Ser A Stat Soc* 2016;179:481–511.
- Cezard G, Sullivan F, Keenan K. Understanding multimorbidity trajectories in scotland using sequence analysis. *Sci Rep* 2022;12:16485.
- Barnett K, Mercer SW, Norbury M, *et al.* Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380:37–43.
- Bzinsky-Fay C, Kohler U. New developments in sequence analysis. *Sociological Methods & Research* 2010;38:359–64.
- Studer M. Weightedcluster library manual: a practical guide to creating typologies of trajectories in the social sciences with R. *LIVES Work Pap* 2013;24.
- Ko JY, Danielson ML, Town M. n.d. Risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization



- surveillance network and behavioral risk factor surveillance system. *Epidemiology*
- 20 Gabadinho A, Ritschard G, Müller NS. n.d. Analyzing and visualizing state sequences in R with traminer. *J Stat Soft*;40.
 - 21 Ginsburgh V, Magerman G, Natali I. COVID-19 and the role of inequality in french regional departments. *Eur J Health Econ* 2021;22:311–27.
 - 22 Atlani-Duault L, Chauvin F, Yazdanpanah Y, et al. France's COVID-19 response: balancing conflicting public health traditions. *The Lancet* 2020;396:219–21.
 - 23 Bajos N, Counil E, Franck J-E, et al. Social inequalities and dynamics of the early COVID-19 epidemic: a prospective cohort study in france. *BMJ Open* 2021;11:e052888.
 - 24 Richard Z, Chabrol F, Gautier L, et al. Considering social inequalities in health in COVID-19 response: insights from a french case study. *Health Promot Int* 2023;38:daac173.
 - 25 Chemtob C, Roitblat HL, Hamada RS, et al. A cognitive action theory of post-traumatic stress disorder. *Journal of Anxiety Disorders* 1988;2:253–75.
 - 26 Buckley TC, Blanchard EB, Neill WT. Information processing and PTSD: a review of the empirical literature. *Clin Psychol Rev* 2000;20:1041–65.
 - 27 Bardeen JR, Daniel TA, Gordon RD, et al. Individual differences in attentional control explain the differential expression of threat-related attentional bias among those with posttraumatic stress symptomatology and predict symptom maintenance up to one year later. *Behav Res Ther* 2020;133:103709.
 - 28 Fernandes S, Fond G, Zendjidian XY, et al. Measuring the patient experience of mental health care: a systematic and critical review of patient-reported experience measures. *Patient Prefer Adherence* 2020;14:2147–61.
 - 29 Wang DE, Tsugawa Y, Figueroa JF, et al. Association between the centers for medicare and medicaid services hospital star rating and patient outcomes. *JAMA Intern Med* 2016;176:848–50.
 - 30 Trzeciak S, Gaughan JP, Bosire J, et al. Association between medicare summary star ratings for patient experience and clinical outcomes in US hospitals. *J Patient Exp* 2016;3:6–9.
 - 31 Jenkinson C, Coulter A, Bruster S, et al. Patients' experiences and satisfaction with health care: results of a questionnaire study of specific aspects of care. *Qual Saf Health Care* 2002;11:335–9.
 - 32 Kingsley C, Patel S. Patient-reported outcome measures and patient-reported experience measures. *BJA Education* 2017;17:137–44.
 - 33 Gleeson H, Calderon A, Swami V, et al. Systematic review of approaches to using patient experience data for quality improvement in healthcare settings. *BMJ Open* 2016;6:e011907.
 - 34 Drain M, Clark PA. Measuring experience from the patient ' s perspective: implications for national initiatives; 2004.
 - 35 Øvretveit J, Zubkoff L, Nelson EC, et al. Using patient-reported outcome measurement to improve patient care. *Int J Qual Health Care* 2017;29:874–9.
 - 36 Fassin D. *Life: A Critical User's Manual* 1st edition. Cambridge, UK ; Medford, MA: Polity, 2018.

Supplementary Material 1

Life-event calendar C-19

Day D0 = First symptom	Clinical History								Health care pathway								
	Cough	Asthenia	Anosmia	Fever	Dyspnea/ Chest discomfort	Headache	Saturation test	Desaturation (saturometer)	Willingness to test	Performing a PCR test	Had the result of a PCR/Ag test (specify the result))	Self- diagnosti c questionn aire	Clinical diagnosis	GP consultatio n (specify if Family practitione r or Emergenc y Services doctor with or without a physical examinatio n)	ED consultation	Phone call to Emergen cy Health Services	Hospi talizat ion
D0																	
D1																	
D2																	
D3																	
D4																	
D5																	
D6																	
D7																	
D8																	
D9																	

PROFIL SOCIO-DEMOGRAPHIQUE DU PATIENT

*** 2 Q1 Quel âge avez-vous ?**

- 📌 Votre réponse doit être comprise entre 18 et 100
- 📌 Seul un nombre entier peut être inscrit dans ce champ.

 ans*** 3 Q2 Etes-vous :**

- 📌 Veuillez sélectionner une réponse ci-dessous

- Un homme
- Une femme

*** 4 Q3 Vivez-vous seul(e) ?**

- Oui
- Non

*** 5 Q4 Quel est votre niveau d'étude ?**

- 📌 Veuillez sélectionner une réponse ci-dessous

- Pas de diplôme
- CAP-BEP
- BAC
- BAC+2 ou plus

*** 6 Q5 Indiquez votre catégorie socio-professionnelle :**

- 📌 Veuillez sélectionner une réponse ci-dessous

- Agriculteurs exploitants
- Artisans, commerçants et chefs d'entreprise
- Cadres et professions intellectuelles supérieures
- Professions Intermédiaires
- Employés
- Ouvriers
- Retraités
- Sans activité professionnelle

*** 7 Q5a Vous êtes actuellement sans activité professionnelle.**

- 📌 Veuillez sélectionner une réponse ci-dessous

- Vous avez déjà eu une activité professionnelle auparavant
- Vous n'avez jamais eu d'activité professionnelle

* 8 Q5b **Avant votre retraite, quelle était votre catégorie socio-professionnelle ?**

📌 Veuillez sélectionner une réponse ci-dessous

- Agriculteurs exploitants
- Artisans, commerçants et chefs d'entreprise
- Cadres et professions intellectuelles supérieures
- Professions Intermédiaires
- Employés
- Ouvriers

* 9 Q6 **Vous êtes en activité ou retraité(e).**

	Oui	Non
Etes-vous ou avez-vous été médecin ?	<input type="radio"/>	<input type="radio"/>
Exercez-vous ou avez-vous exercé une profession paramédicale ?	<input type="radio"/>	<input type="radio"/>

* 10 Q8 **Avez-vous, dans votre entourage (familial ou amical), une personne travaillant dans le milieu médical ou paramédical susceptible de vous conseiller ?**

- Oui
- Non

📌 Exemple : médecin, infirmier...

PROFIL SANTE

* 11 Q9 **Actuellement, avez-vous une maladie pour laquelle vous avez un traitement et/ou un suivi médical ?**

- Oui
- Non

*** 12 Q10 Indiquez les maladies que vous avez actuellement :**

Cochez la ou les réponses

- | | |
|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| <input type="checkbox"/> Cancer en cours de traitement (quel que soit le type) | <input type="checkbox"/> Maladie de Parkinson |
| <input type="checkbox"/> Diabète | <input type="checkbox"/> Epilepsie |
| <input type="checkbox"/> Insuffisance rénale sous dialyse | <input type="checkbox"/> Lupus érythémateux disséminé |
| <input type="checkbox"/> Hypertension artérielle | <input type="checkbox"/> Polyarthrite rhumatoïde |
| <input type="checkbox"/> Insuffisance cardiaque | <input type="checkbox"/> Sarcoïdose |
| <input type="checkbox"/> Troubles du rythme cardiaque | <input type="checkbox"/> Maladie de Horton |
| <input type="checkbox"/> Asthme | <input type="checkbox"/> Syndrome de Raynaud |
| <input type="checkbox"/> Maladie chronique pulmonaire (BPCO et insuffisance respiratoire) | <input type="checkbox"/> Syndrome de Gougerot-Sjögren |
| <input type="checkbox"/> Cirrhose du foie | <input type="checkbox"/> Mutation du facteur de Leiden |
| <input type="checkbox"/> Hépatite chronique | <input type="checkbox"/> Maladie de Marfan |
| <input type="checkbox"/> Dépression | <input type="checkbox"/> Maladie d'Addison |
| <input type="checkbox"/> Ulcère gastrique | <input type="checkbox"/> Maladie articulaire : rhumatisme |
| <input type="checkbox"/> Hypothyroïdie | <input type="checkbox"/> Apnée du sommeil nécessitant de l'oxygène |
| <input type="checkbox"/> Hyperthyroïdie | <input type="checkbox"/> Autre : <input type="text"/> |

*** 13 Q11 Avez-vous eu une ou plusieurs maladies dans le passé ?** Oui Non*** 14 Q12 Indiquez la ou les maladies que vous avez eues dans le passé :**

Cochez la ou les réponses

- | | |
|---------------------------------------------------------------------|---------------------------------------------------------|
| <input type="checkbox"/> Embolie pulmonaire | <input type="checkbox"/> Cancer datant de plus de 5 ans |
| <input type="checkbox"/> Infarctus du myocarde | <input type="checkbox"/> Anévrisme de l'aorte |
| <input type="checkbox"/> Accident Vasculaire Cérébral (AVC) | <input type="checkbox"/> Anévrisme de la carotide |
| <input type="checkbox"/> Accident Ischémique Transitoire (AIT) | <input type="checkbox"/> Greffe d'organe |
| <input type="checkbox"/> Artérite oblitérante des membres inférieur | <input type="checkbox"/> Thrombose veineuse profonde |
| <input type="checkbox"/> Troubles du rythme cardiaque | <input type="checkbox"/> Phlébite |
| <input type="checkbox"/> Cancer datant de moins de 5 ans | <input type="checkbox"/> Autre : <input type="text"/> |

* 15 Q12bis Vous avez eu un AVC dans le passé.

A ce jour, avez-vous des séquelles ?

Oui Non

* 16 Q13 Veuillez répondre aux questions suivantes sur votre profil :

	Oui	Non
Etes-vous immunodéprimé(e)*	<input type="radio"/>	<input type="radio"/>
Prenez-vous des médicaments tous les jours ?	<input type="radio"/>	<input type="radio"/>
Actuellement fumez-vous ?	<input type="radio"/>	<input type="radio"/>
Buvez-vous plus de 2 verres d'alcool par jour tous les jours ?	<input type="radio"/>	<input type="radio"/>

*Une personne est immunodéprimée quand son système immunitaire ne fonctionne pas bien et qu'elle est donc plus vulnérable aux infections.

* 17 Q13a Combien de médicaments prenez-vous par jour ?

ⓘ Votre réponse doit être comprise entre 1 et 20

ⓘ Seul un nombre entier peut être inscrit dans ce champ.

médicaments par jour

* 18 Q13b Combien de cigarettes fumez-vous par jour ?

ⓘ Votre réponse doit être comprise entre 1 et 99

ⓘ Seul un nombre entier peut être inscrit dans ce champ.

cigarettes par jour

* 19 Q14 Indiquez :

ⓘ Seuls les nombres sont acceptés.

Votre taille (en cm)

Votre poids (en kg)

ⓘ Exemple : pour 1m60, indiquez 160cm.

* 20 Q15 Avez-vous un médecin traitant ?

Oui Non

* 21 Q16 Quelle relation de confiance avez-vous avec votre médecin traitant ?

ⓘ Veuillez sélectionner une réponse ci-dessous

- Excellente
- Normale
- Mauvaise
- Très mauvaise

22 Q17 **Avez-vous des difficultés à avoir un rendez-vous avec votre médecin traitant ?**

📌 Veuillez sélectionner une réponse ci-dessous

- Jamais
- Parfois
- Souvent
- Tout le temps

* 23 Q18 **Au cours d'une année, combien de fois allez-vous consulter (hors contexte covid 19) ?**

	Une fois	Plusieurs fois	Jamais
Votre médecin traitant / Un médecin généraliste	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Un médecin spécialiste (gynécologue, cardiologue...)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Un ostéopathe	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Un homéopathe	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Un naturopathe	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

* 24 Q19 **Durant les 5 dernières années, avez-vous eu des séjours hospitaliers (hors Covid-19) ?**

📌 Veuillez sélectionner une réponse ci-dessous

- Oui, une fois
- Oui, plusieurs fois
- Non, aucun

📌 Un séjour = au moins une nuit à l'hôpital

CIRCONSTANCES DE DECOUVERTE DE LA CONTAMINATION PAR LE COVID-19

* 25 Q20 **Vous avez découvert que vous aviez le COVID-19 :**

📌 Veuillez sélectionner une réponse ci-dessous

- A l'occasion d'un dépistage pour des raisons personnelles/administratives (voyage, travail, fête de famille...)
- A l'occasion d'un dépistage car vous étiez cas contact
- À la suite de l'apparition de symptômes

* 26 Q21 **Combien de jours, approximativement, se sont écoulés entre le résultat de votre test et les premiers symptômes ?**

📌 Seul un nombre entier peut être inscrit dans ce champ.

j

* 27 Q22 **Avant de savoir que vous aviez le COVID-19, avez-vous réalisé, la semaine précédente, des tests de dépistage COVID qui se sont avérés négatifs ?**

- Oui Non

* 28 Q22a **Combien de tests, dont le résultat était négatif, avez-vous réalisés ?**

📌 Seul un nombre entier peut être inscrit dans ce champ.

tests

* 29 Q22b **Parmi ces tests dont les résultats étaient négatifs, lesquels avez-vous réalisés ?**

📌 Cochez la ou les réponses

Test antigénique (en pharmacie)

Test PCR

Auto-test

N.B. : Questions 29, 30 et 31 identiques car conditionnelles selon le nombre de tests réalisés à Q22a

DELAI 1er SYMPTOME - HOSPITALISATION

* 32 Q0 **Combien de jours se sont écoulés entre l'apparition de votre 1er symptôme (J0) et votre hospitalisation pour COVID-19 ?**

📌 Votre réponse doit être comprise entre 1 et 16

📌 Seul un nombre entier peut être inscrit dans ce champ.

j

📌 *Minimum* : 1 jour

Maximum : 16 jours

33 Q0conf **Vous avez été hospitalisé(e) jours après l'apparition du 1er symptôme (J0)**

📌 Si cette durée est erronée, modifier la réponse à la question précédente.

* 34 Q0a **Entre l'apparition du 1er symptôme (J0) et votre hospitalisation (J), étiez-vous en période d'isolement ailleurs qu'à votre domicile (hôtel, centre de vacances...)?**

Oui Non

N.B. : Questions 35 à 38 de type équationnelles avec code JavaScript, invisibles à l'écran

SYMPTÔME INITIAL (J0)

* 39 QTEST02 Selon vous, quel symptôme est apparu en **premier** (J0) ?

ⓘ Veuillez sélectionner une réponse ci-dessous

Veillez choisir ...

Veillez choisir ...

- Perte de gout ou d'odorat
- Toux / mal de gorge
- Fièvre modérée (38 à 40°)
- Fièvre intense (supérieure à 40°)
- Céphalées modérées (maux de tête)
- Céphalées intenses
- Nausées modérées
- Nausées intenses empêchant l'alimentation
- Diarrhée
- Difficultés à respirer
- Difficultés à respirer intense (sensation d'étouffer)
- Courbatures
- Fatigue modérée
- Fatigue intense (difficulté à se déplacer, s'alimenter)
- Perte de connaissance
- Confusion

SYMPTÔMES

* 40 QTEST11 Sélectionnez **tous les symptômes** que vous avez eus, depuis l'apparition du **1er symptôme (J0) jusqu'à votre hospitalisation (J)** :

Rappel de votre 1er symptôme à J0 :

ⓘ Cochez la ou les réponses

- | | |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Perte de gout ou d'odorat | <input type="checkbox"/> Difficultés à respirer |
| <input type="checkbox"/> Toux / mal de gorge | <input type="checkbox"/> Difficultés à respirer intense (sensation d'étouffer) |
| <input type="checkbox"/> Fièvre modérée (38 à 40°) | <input type="checkbox"/> Courbatures |
| <input type="checkbox"/> Fièvre intense (supérieure à 40°) | <input type="checkbox"/> Fatigue modérée |
| <input type="checkbox"/> Céphalées modérées (maux de tête) | <input type="checkbox"/> Fatigue intense (difficulté à se déplacer, s'alimenter) |
| <input type="checkbox"/> Céphalées intenses | <input type="checkbox"/> Perte de connaissance |
| <input type="checkbox"/> Nausées modérées | <input type="checkbox"/> Confusion |
| <input type="checkbox"/> Nausées intenses empêchant l'alimentation | <input type="checkbox"/> Désaturation (inférieure à 90) par oxymètre de pouls*/prise de sang |
| <input type="checkbox"/> Diarrhée | |

ⓘ *Oxymètre de pouls :



* 41 QTEST14 Indiquez le **jour d'apparition** de chacun de ces symptômes et **la durée* de chacun d'entre eux, depuis l'apparition du 1er symptôme (J0), jusqu'à votre hospitalisation (J)** pour COVID-19 :

RAPPEL de votre 1er symptôme à J0 :

* Pour indiquer la durée, cochez le nombre de cases qui correspondent à la durée du symptôme (exemple ci-dessous)

	J0
Perte de gout ou d'odorat	<input type="checkbox"/>
Toux / mal de gorge	<input type="checkbox"/>
Fièvre modérée (38 à 40°)	<input type="checkbox"/>
Fièvre intense (supérieure à 40°)	<input type="checkbox"/>
Céphalées modérées (maux de tête)	<input type="checkbox"/>
Céphalées intenses	<input type="checkbox"/>
Nausées modérées	<input type="checkbox"/>
Nausées intenses empêchant l'alimentation	<input type="checkbox"/>
Diarrhée	<input type="checkbox"/>
Difficultés à respirer	<input type="checkbox"/>
Difficultés à respirer intense (sensation d'étouffer)	<input type="checkbox"/>
Courbatures	<input type="checkbox"/>
Fatigue modérée	<input type="checkbox"/>
Fatigue intense (difficulté à se déplacer, s'alimenter)	<input type="checkbox"/>
Perte de connaissance	<input type="checkbox"/>
Confusion	<input type="checkbox"/>
Désaturation (inférieure à 90) par oxymètre de pouls*/prise de sang	<input type="checkbox"/>

Exemple :

J'ai été hospitalisé à J6, soit 6 jours après l'apparition de mon 1er symptôme (J0).

J'ai eu de la toux à J0, **pendant 4 jours**, puis des difficultés à respirer de J4 à J6 (**durée totale de 3 jours**).

Enfin, j'ai eu **4 jours** de courbatures, à J0 et J1, puis de nouveau de J5 à J6.

	J0	J1	J2	J3	J4	J5	J6
Toux / mal de gorge	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Difficultés à respirer intense (sensation d'étouffer)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Courbatures	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

RECOURS ACTES ET SERVICES

* 42 QTEST21 Parmi ces propositions, sélectionnez tous les actes / services auxquels vous avez eu recours, depuis l'apparition du symptôme initial (J0) jusqu'à votre hospitalisation (J) :

🔍 Cochez la ou les réponses

- | | |
|----------------------------------------------------------------------|---------------------------------------------------------------|
| <input type="checkbox"/> Réalisation(s) test(s) antigénique(s) | <input type="checkbox"/> Consultation dans un centre de santé |
| <input type="checkbox"/> Réalisation(s) test(s) PCR | <input type="checkbox"/> Consultation IHU |
| <input type="checkbox"/> Résultat(s) test(s) antigénique(s) | <input type="checkbox"/> Consultation CHU Nice |
| <input type="checkbox"/> Résultat(s) test(s) PCR | <input type="checkbox"/> Consultation SOS Médecins |
| <input type="checkbox"/> Consultation médecin généraliste en cabinet | <input type="checkbox"/> Consultation au service d'urgence |
| <input type="checkbox"/> Appel médecin généraliste pour conseil | <input type="checkbox"/> Appel SAMU (15) |
| <input type="checkbox"/> Téléconsultation médecin généraliste | <input type="checkbox"/> Appel Pompiers (18) |

* 43 Q1J14 Veuillez indiquer les différents actes et services que vous avez utilisés, depuis l'apparition du 1er symptôme (J0) jusqu'à votre hospitalisation (J) :

	J0
Réalisation(s) test(s) antigénique(s)	<input type="checkbox"/>
Réalisation(s) test(s) PCR	<input type="checkbox"/>
Résultat(s) test(s) antigénique(s)	<input type="checkbox"/>
Résultat(s) test(s) PCR	<input type="checkbox"/>
Consultation médecin généraliste cabinet	<input type="checkbox"/>
Appel médecin généraliste pour conseil	<input type="checkbox"/>
Téléconsultation médecin généraliste	<input type="checkbox"/>
Consultation dans un centre de santé	<input type="checkbox"/>
Consultation IHU	<input type="checkbox"/>
Consultation CHU Nice	<input type="checkbox"/>
Consultation SOS Médecins	<input type="checkbox"/>
Consultation au service d'urgence	<input type="checkbox"/>
Appel SAMU (15)	<input type="checkbox"/>
Appel Pompiers (18)	<input type="checkbox"/>

🔍 Exemple :

J'ai fait un test PCR à J0, et j'ai eu les résultats le lendemain, à J1.

J'ai pris un RDV avec mon médecin généraliste à J3, puis un autre RDV à J7.

Enfin, j'ai appelé le SAMU à J9, le jour de mon hospitalisation.

	J0	J1	J2	J3	J4	J5	J6	J7	J8	J9
Recours aux tests PCR	☑	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Résultats du test PCR	<input type="checkbox"/>	☑	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Prise RDV consultation médecin généraliste	<input type="checkbox"/>	<input type="checkbox"/>	☑	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	☑	<input type="checkbox"/>	<input type="checkbox"/>
Appel SAMU (15)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	☑

TRAITEMENT / EXAMENS / BILANS

44 QTEST32 **Sélectionnez tous les traitements / examens / bilans que vous avez eus, depuis l'apparition du 1er symptôme (J0) jusqu'à votre hospitalisation (J) :**

📌 Cochez la ou les réponses

- | | |
|------------------------------------------------------------------------|---------------------------------------------------------------------|
| <input type="checkbox"/> Antibiotiques | <input type="checkbox"/> Oxygène à domicile ou en service d'urgence |
| <input type="checkbox"/> Anticoagulants | <input type="checkbox"/> Vitamine D |
| <input type="checkbox"/> Bilan biologique réalisé | <input type="checkbox"/> Zinc |
| <input type="checkbox"/> Corticoïdes | <input type="checkbox"/> Protocole IHU / Protocole "Raoult" |
| <input type="checkbox"/> Paracétamol (Doliprane, Dafalgan, Efferalgan) | <input type="checkbox"/> Aucun |
| <input type="checkbox"/> Examen radiologique/Scanner réalisé | |

*45 QTEST33 **Indiquez, parmi les traitements / examens / bilans sélectionnés, le début et la durée de chacun d'entre eux, depuis l'apparition du symptôme initial (J0) jusqu'à votre hospitalisation (J) :**

	J0
Antibiotiques	<input type="checkbox"/>
Anticoagulants	<input type="checkbox"/>
Bilan biologique réalisé	<input type="checkbox"/>
Corticoïdes	<input type="checkbox"/>
Paracétamol (Doliprane, Dafalgan, Efferalgan)	<input type="checkbox"/>
Examen radiologique/Scanner réalisé	<input type="checkbox"/>
Oxygène à domicile ou en service d'urgence	<input type="checkbox"/>
Vitamine D	<input type="checkbox"/>
Zinc	<input type="checkbox"/>
Protocole IHU / Protocole "Raoult"	<input type="checkbox"/>

📌 Exemple :

J'ai pris du Paracétamol dès l'apparition des symptômes à J0, jusqu'à J2, puis de J5 à J6 (durée totale de traitement de 5j).

J'ai ensuite pris de la Vitamine D à J1, J3 et J5 (donc pendant 3 jours).

Enfin, j'ai réalisé un bilan biologique à J4.

	J0	J1	J2	J3	J4	J5	J6
Bilan biologique réalisé	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Paracétamol (Doliprane, Dafalgan,...)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Vitamine D	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

* 46 QTEST34 Parmi les traitements suivants, indiquez s'ils ont été pris :

	Sur prescription médicale	En automédication
Antibiotiques	<input type="radio"/>	<input type="radio"/>
Anticoagulants	<input type="radio"/>	<input type="radio"/>
Corticoides	<input type="radio"/>	<input type="radio"/>
Paracétamol (Doliprane, Dafalgan, Efferalgan)	<input type="radio"/>	<input type="radio"/>
Vitamine D	<input type="radio"/>	<input type="radio"/>
Zinc	<input type="radio"/>	<input type="radio"/>

📌 **Automédication** : utilisation, hors prescription médicale, de médicaments.

PRISE EN CHARGE

* 47 Q23 Durant la période où vous aviez le Covid et que vous étiez à votre domicile, étiez-vous accompagné(e) (prise de nouvelles, visites régulières, appels...)?

Oui Non

* 48 Q24 Qu'est-ce qui a déclenché votre hospitalisation ?

📌 Veuillez sélectionner une réponse ci-dessous

📌 Au besoin, veuillez préciser le champ 'Autre' :

- Médecin généraliste
- Votre médecin traitant
- Appel SOS médecin/Pompier
- Après une consultation d'urgence
- Ma famille
- Moi-même
- Mes ami(e)s
- Autre :

* 49 Q24b Selon vous, avant de contracter le Covid, comment jugeriez-vous votre comportement pour éviter la contamination ?

📌 Veuillez sélectionner une réponse ci-dessous

- Extrêmement prudent
- Très prudent
- Moyennement prudent
- Ni prudent ni imprudent
- Moyennement imprudent
- Très imprudent
- Extrêmement imprudent

* 50 Q25 **Selon vous, avant de vous faire hospitaliser :**

	Oui	Non
Avez-vous eu conscience de la gravité de votre état de santé ?	<input type="radio"/>	<input type="radio"/>
Avez-vous rencontré des difficultés pour voir un médecin ?	<input type="radio"/>	<input type="radio"/>
Avez-vous rencontré des difficultés pour vous faire soigner ?	<input type="radio"/>	<input type="radio"/>

* 51 Q26 **Avec le recul, quel est votre niveau de satisfaction concernant votre prise en charge médicale avant d'être hospitalisé(e) ?**

📌 Veuillez sélectionner une réponse ci-dessous

- Très satisfait
- Plutôt satisfait
- Ni satisfait, ni insatisfait
- Plutôt insatisfait
- Très insatisfait
- Non concerné

* 52 Q0a3 **Vous avez été hospitalisé(e) pour Covid-19 :**

📌 Cochez la ou les réponses

- A l'ITHU de Marseille
- Au CHU de Nice

* 53 Q0a4 **Quand avez-vous été hospitalisé(e) ?**

Format : mm/yyyy

📌 Indiquez le mois et l'année

* 54 Q0b **Combien de jours avez-vous été hospitalisé(e) pour cet épisode de Covid-19 ?**

📌 Seul un nombre entier peut être inscrit dans ce champ.

 j

* 55 Q0c **Au cours de votre séjour à l'hôpital, vous étiez en :**

📌 Veuillez sélectionner une réponse ci-dessous

- Réanimation
- Soins intensifs
- Aucun de ces choix

* 56 Q27 **Après votre hospitalisation, avez-vous fait un séjour en Soins de Suite et de Réadaptation (SSR) ?**

- Oui
- Non

* 57 Q28 Lorsque vous êtes rentré(e) à votre domicile, avez-vous eu besoin :

	Oui	Non
D'oxygène à domicile	<input type="radio"/>	<input type="radio"/>
De rééducation	<input type="radio"/>	<input type="radio"/>

* 58 Q29 Par rapport aux hommes/femmes de votre âge, vous pensiez que votre risque d'attraper le Covid était :

ⓘ Veuillez sélectionner une réponse ci-dessous

Veillez choisir ...

Veillez choisir ...

- Beaucoup moins important que pour les autres hommes/femmes de mon âge
- Moins important que pour les autres hommes/femmes de mon âge
- Ni plus ni moins important que pour les autres hommes/femmes de mon âge
- Plus important que pour les autres hommes/femmes de mon âge
- Beaucoup plus important que pour les autres hommes/femmes de mon âge

* 59 Q30 Actuellement, avez-vous toujours des séquelles du Covid ?

Oui Non

* 60 Q30bis Quelles séquelles avez-vous ?

ⓘ Cochez la ou les réponses

- Physiques (difficulté à respirer, fatigue)
- Neurologiques (perte de mémoire, troubles de la concentration)
- Psychologiques (dépression, anxiété)
- Troubles du sommeil, insomnies
- Autre :


* 61 Q31 Depuis la fin de votre hospitalisation :

	Oui	Non
Avez-vous repris votre vie comme avant ?	<input type="radio"/>	<input type="radio"/>
Avez-vous à nouveau été infecté(e) par le Covid-19 ?	<input type="radio"/>	<input type="radio"/>

62 Q32 Avez-vous des remarques / informations complémentaires à faire sur votre parcours pré-hospitalier ?

Supplementary material 2. Clusters of symptom sequences - Hierarchical cluster analysis (n=312)

Inertia plot



Dendrogram

